Up date in the management of advanced ovarian carcinoma

Critical Reviews in Oncology/Hematology

Volumn 32, Issue 1, 1999, Pages 49-58

  Conte, P F ^a   Cianci, C ^a   Gadducci, A ^b  

^a Division of Medical Oncology   (Italy)

^b Div of Gynecology and Obstetrics   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; MELPHALAN; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG MEGADOSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; OVARY CARCINOMA; PALLIATIVE THERAPY; REVIEW; SECOND LOOK SURGERY; SURGICAL APPROACH;

EID: 0032828660     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(99)00036-0     Document Type: Article

References (111)

1. Hoskins W.J., Rubin S.C. Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol. 18:1991;213-221.
2. Hoskins W.J. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer. 71:1993;1534-1540.
3. Neijt J.P., ten Bokkel Huinink W.W., van der Burg M.E. et al. Randomized trial comparing two combination chemotherapy regimens (HEXA-CAF vs CHAP-5) in advanced ovarian cancer. Lancet. ii:1984;594-600.
4. Edmonson J.H., McCormack G.M., Fleming T.R. et al. Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas. Cancer Treat Rep. 69:1985;1243-1248.
5. Conte P.F., Bruzzone M., Chiara S. et al. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin,doxorubicin and cyclophosphamide in advanced ovarian cancer. J Clin Oncol. 4:1986;965-971.
6. Neijt J.P., ten Bokkel Huinink W.W., van der Burg M.E. et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 vs CP) in advanced ovarian carcinoma. J Clin Oncol. 5:1987;1157-1168.
7. Bertelsen K., Jacobsen A., Andersen J.E. et al. A randomized study of cyclophosphamide and cisplatin with or without doxorubicin in advanced ovarian cancer. Gynecol Oncol. 26:1987;161-169.
8. Randomized comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet. ii:1987;353-359.
9. Omura G., Bundy B.M., Berek J.S. et al. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 7:1989;457-465.
10. Mangioni C., Bolis G., Pecorelli S. et al. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst. 81:1989;1464-1471.
11. Alberts D.S., Green S., Hanningan E.V. et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomised trial in stage III and IV ovarian cancer. J Clin Oncol. 10:1992;706-717.
12. Conte P.F., Bruzzone M., Carnino F. et al. Carboplatin, doxorubicin and cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma. J Clin Oncol. 9:1991;658-663.
13. Swenerton K., Jeffrey J., Stuart G. et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomised phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 10:1992;718-726.
14. Taylor A.E., Wiltshaw E., Gore M. et al. Long-term follow-up of the first randomised study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol. 12:1994;2066-2070.
15. McGuire W.P., Hoskins W.J., Brady M.F. et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med. 334:1996;1-6.
16. Baker T.R., Piver M.S., Hempling R.E. Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma. Cancer. 74:1994;656-663.
17. Gershenson D.M., Copeland L.J., Wharton J.T. et al. Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer. 55:1985;1129-1135.
18. Podratz K.C., Malkasian G.D. Jr., Wieand H.S. et al. Recurrent disease after negative second-look laparotomy in stage III and IV ovarian carcinoma. Gynecol Oncol. 29:1988;274-282.
19. Lund B., Williamson P. Prognostic factors for outcome of and survival after second-look laparotomy in patients with advanced ovarian carcinoma. Obstet Gynecol. 76:1990;617-622.
20. Potter M.E., Hatch K.D., Soong S.J. et al. Second-look laparotomy and salvage therapy: a research modality only? Gynecol Oncol. 44:1992;3-9.
21. Bar-Am A., Kovner F., Lessing J.B. et al. A second thought on second look laparotomy. Acta Obstet Gynecol Scand. 72:1993;386-390.
22. Chiara S., Lionetto R., Campora E. et al. Long-term prognosis following macroscopic complete response at second-look laparotomy in advanced ovarian cancer patients treated with platinum-based chemotherapy. Eur J Cancer. 3:1995;296-301.
23. Gadducci A., Sartori E., Maggino T. et al. Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study. Gynecol Oncol. 68:1998;150-155.
24. Annual report on the results of treatment in gynecological cancer. J Epidemiol Biostat. 23:1998;1.
25. Ovarian cancer. Screening, treatment and follow-up. J Am Med Assoc. 273:1995;491-497.
26. Griffiths C.T. Surgical cytoreduction of ovarian cancer. Conte P.F., Ragni N., Rosso R., Vermorken J.B. Multimodal treatment of ovarian cancer. 1989;133-141 Raven Press, New York.
27. Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol. 38:1990;203-209.
28. Makar A.P., Baekelandt M., Trope' C.G., Kristensen G.B. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol. 56:1995;175-180.
29. Liu P.C., Benjamin I., Morgan M.A. et al. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol. 64:1997;4-8.
30. Curtin J.P., Malik R., Venkatraman N.S. et al. Stage IV ovarian cancer: Impact of surgical debulking. Gynecol Oncol. 64:1997;9-12.
31. Munkarah A.R., Hallum A.V., Morris M. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol. 64:1997;13-17.
32. Eisenkop S.M., Friedman R.L., Wang H.J. et al. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 69:1998;103-108.
33. Goldberg G.L., Schneiner B.A., Friedman A. et al. Lymph node sampling in patients with epithelial ovarian carcinoma. Gynecol Oncol. 47:1995;143-145.
34. Carnino F., Fuda G., Ciccone G. et al. Significance of lymph node sampling in epithelial carcinoma of the ovary. Gynecol Oncol. 65:1997;467-472.
35. Burghardt E., Pickel H., Stettner H. Management of ovarian cancer. Eur J Gynaecol Oncol. 3:1984;155-159.
36. Benedetti Panici P., Greggi S., Scambia G. et al. Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer. Gynecol Oncol. 51:1993;150-154.
37. Scarabelli C., Gallo A., Zarelli A. et al. Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival. Gynecol Oncol. 56:1995;328-337.
38. Shepherd J.H. Surgical management of ovarian cancer. Shepherd J.H., Monaghan J.M. Clinical gynaecological oncology. 2nd ed. 1990;218-246 Blackwell Scientific, Oxford.
39. Monaghan J.M. Surgical techniques used in achieving optimal resection of stage III cancer of the ovaries. Baillieres Clin Obstet Gynaecol. 3:1989;39-57.
40. Griffiths C.T., Finkler N.J. Surgery for carcinoma of the ovary: extrapelvic cytoreduction. Coppleson M. Gynecologic Oncology. 1992;313-333 Churchill Livingstone, Edinburgh.
41. Nelson B.E., Rosenfield A.T., Schwartz P.E. Preoperative abdominopelvic computed tomographic preduction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol. 11:1993;166-172.
42. Benedetti-Panici P.L., Maneschi F., Scambia G. et al. The pelvic retroperitoneal approach in the treatment of advanced ovarian carcinoma. Obstet Gynecol. 87:1996;532-538.
43. van der Burg M.E.L., van Lent M., Buyse M. et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. New Engl J Med. 332:1995;629-634.
44. van der Burg M.E.L., van Lent M., Kobierska A. et al. After 6 years follow-up intervention debulking surgery remains an independent prognostic factor for survival in advanced epithelial ovarian cancer: an EORTC Gynecologic Cancer Cooperative Group Study. Int J Gynecol Cancer. 7(Suppl. 2):1997;28. [abstract 078].
45. Landoni F., Maggioni A., Benedetti Panici P.L. et al. Randomized trial of lymphadenectomy (LY) vs sampling (SA) as surgical staging procedure at second-look in epithelial ovarian cancer. Proc Am Soc Clin Oncol. 17:1998;360. [abstract 1390].
46. Hoskins W.J., Rubin S.C., Dulaney E. et al. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. Gynecol Oncol. 34:1989;365-371.
47. Maggioni A., Colombo N., Parma G. et al. The role of secondary cytoreduction (SC) in advanced ovarian cancer: long-term follow-up. Int J Gynecol Cancer. 7(Suppl. 2):1997;28. [abstract 079].
48. Williams L., Brunetto V.L., Yordan E. et al. Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 66:1997;171-178.
49. Hainsworth J.D., Grosh W.M., Burnett L.S. et al. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann Intern Med. 108:1988;165.
50. Chambers S.K., Chambers J.T., Kohorn E.I. et al. Evaluation of the role of second-look surgery in ovarian cancer. Obstet Gynecol. 72:1988;404-408.
51. Morgan M.A., Rubin S.C. Secondary cytoreduction in epithelial ovarian cancer. Crit Rev Oncol Hematol. 18:1995;1-8.
52. Clarke-Pearson D.L., Chin N.O., DeLong E.R. et al. Surgical management of intestinal obstruction in ovarian cancer. I. Clinical features, postoperative complications, and survival. Gynecol Oncol. 26:1987;11-18.
53. Beattie G.J., Leonard R., Smith J.F. Bowel obstruction in ovarian carcinoma: a retrospective study and review of the literature. J Palliat Care. 3:1989;275-280.
54. Ripamonti C. Management of bowel obstruction in advanced cancer. Curr Opin Oncol. 6:1994;351-357.
55. Lund B., Hansen M., Lundvall F. et al. Intestinal obstruction in patients with advanced carcinoma of the ovaries treated with combination chemotherapy. Surg Gynecol Obstet. 169:1989;213-218.
56. Krebs H.B., Goplerud D.R. Surgical management of bowel obstruction in advanced ovarian carcinoma. Obstet Gynecol. 61:1983;327-330.
57. Fernandes J.R., Seymour R.J., Suissa S. Bowel obstruction in patients with ovarian cancer: a search for prognostic factors. Am J Obstet Gynecol. 158:1988;244-249.
58. Rubin S.C., Hoskins W.J., Benjamin I., Lewis J.L. Jr. Palliative surgery for intestinal obstruction in advanced ovarian cancer. Gynecol Oncol. 34:1989;16-19.
59. Jong P., Sturgeon J., Jamieson C.G. Benefit of palliative surgery for bowel obstruction in advanced ovarian cancer. Can J Surg. 38:1995;454-457.
60. Ripamonti C., De Conno F., Ventafridda V. et al. Management of bowel obstruction in advanced and terminal cancer patients. Ann Oncol. 4:1993;15-21.
61. Gadducci A., Iacconi P., Fanucchi A. et al. Survival after intestinal obstruction in patients with fatal ovarian cancer: analysis of prognostic variables. Int J Gynecol Cancer. 8:1998;177-182.
62. Campagnutta E., Cannizzaro R., Gallo A. et al. Palliative treatment of upper intestinal obstruction by gynecological malignancy: the usefulness of percutaneous endoscopic gastrostomy. Gynecol Oncol. 62:1996;103-105.
63. Hawkins R.E. Chemotherapy for ovarian cancer - trials, controversies and funding. Br J Cancer. 78:1998;1402-1403.
64. Adams M., Calvert A.H., Carmichael J. et al. Chemotherapy for ovarian cancer - a consensus statement on standard practice. Br J Cancer. 78:1998;1404-1406.
65. Sandercock J., Parmar M.K.B., Torri V. First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. Br J Cancer. 78:1998;1471-1478.
66. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br Med J. 303:1991;884-893.
67. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Br J Cancer. 78:1998;1479-1487.
68. Cyclophosphamide plus cisplatin versus cyclophosphamide,doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol. 9:1991;1668-1674.
69. A'Hern R.P., Gore M.E. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol. 13:1995;726-732.
70. Icon II: randomized trial of single agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet. 352:1998;1571-1576.
71. Levin L., Hryniuk W.M. Dose-intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol. 5:1987;756-767.
72. Kaye S.B., Lewis C.R., Paul J. et al. Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet. 340:1992;329-333.
73. McGuire W.P., Hoskins W.J., Brady M.F. et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer. J Clin Oncol. 13:1995;1588-1599.
74. Colombo N., Pittelli M.R., Parma G. et al. Cisplatin (p) dose-intensity in advanced ovarian cancer: a randomized study of conventional dose vs dose intense cisplatin chemotherapy. Proc Am Soc Clin Oncol. 12:1993;255. [abstract 806[.
75. Conte P.F., Bruzzone M., Carnino F. et al. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol. 14:1996;351-356.
76. Ben-David Y., Rosen B., Frassen E. et al. Meta-analysis comparing cisplatin total dose intensity and survival. Gynecol Oncol. 59:1995;93-101.
77. Alberts D.S., Liu P.Y., Hannigan E.V. et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New Engl J Med. 335:1996;1950-1955.
78. Markman M., Bundy B., Benda J. et al. Randomized phase 3 study of intravenous (iv) cisplatin (CIS)/ paclitaxel (PAC) versus moderately high dose iv carboplatin (CARB) followed by iv PAC and intraperitoneal (ip) CIS in optimal residual ovarian cancer (OC): an intergroup trial (GOG, SWOG, ECOG). Proc Am Soc Clin Oncol. 17:1998;361. [abstract 1392].
79. Gadducci A., Carnino F., Chiara S. et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest (GONO). Gynecol Oncol (submitted for pubblication).
80. Stuart G., Bertelsen K., Mangioni C. et al. Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup trial. Proc Am Soc Clin Oncol. 17:1998;361. [abstract 1394].
81. Muggia F.M., Braly P.S., Brady M.F. et al. Phase III of cisplatin (P) or paclitaxel (T), versus their combination in suboptimal stage III and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study 132. Proc Am Soc Clin Oncol. 16:1997;352. [abstract 1257].
82. Harper P. A randomised comparison of Paclitaxel (T) and Carboplatin (J) versus a control arm of single agent carboplatin (J) or CAP (cyclophosphamide, doxorubicin and cisplatin): 2075 patients into the 3rd International Collaborative Ovarian Neoplasm Study (ICON3). Proc Am Soc Clin Oncol. 18:1999;356. [abstract 1375].
83. Neijt J.P., Hansen M., Hansen S.W. et al. Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIb, IIc, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin. Proc Am Soc Clin Oncol. 16:1997;352. [abstract 1259].
84. Ozols R.F., Bundy B.N., Fowler J. et al. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group Trial (GOG 158). Proc Am Soc Clin Oncol. 18:1999;356. [abstract 1373].
85. du Bois A., Luck H.J., Meier W. et al. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: update of an Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Study Group Trial. Proc Am Soc Clin Oncol. 18:1999;356. [abstract 1374].
86. du Bois A., Luck H.J., Bauknecht T. et al. First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. J Clin Oncol. 17:1999;46-51.
87. Brunetti I., Tanganelli L., Romanini A. et al. Epidoxorubicin (EPIDX), carboplatin (CBDCA) and paclitaxel (PTX) in advanced epithelial ovarian cancer (AEOC). Proc Am Soc Clin Oncol. 17:1998;350. [abstract 1350].
88. Hansen S.W., Anderson H., Boman K. et al. Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV. Proc Am Soc Clin Oncol. 18:1999;357. [abstract 1379].
89. Burris H.A. III, Fields S.M. Topoisomerase I inhibitors: an overview of the camptothecin analogs. Hematol Oncol Clin North Am. 8:1994;333-355.
90. Creemers G.J., Bolis G., Gore M. et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol. 14:1996;3056-3061.
91. Carmichael J., Gordon A., Malfetano J. et al. Topotecan, a new active drug, vs. paclitaxel in advanced epithelial ovarian carcinoma: International Topotecan Study Group Trial. Proc Am Soc Clin Oncol. 15:1996;283.
92. Hochster H., Speyer J., Wadler S. et al. Phase II study of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer: a highly active regimen. Proc Am Soc Clin Oncol. 15:1996;285.
93. Gordon A., Bookman M., Malmstrom H. et al. Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group Trial. Proc Am Soc Clin Oncol. 15:1996;282.
94. Huinink W.T.B., Gore M., Carmichael J. et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 15:1997;2183-2193.
95. Neijt J.P., Kaufmann M., Bauknecht T. et al. Gemcitabine in pretreated ovarian cancer. Ann Oncol. 7(Suppl. 5):1996;70. [abstract 329P].
96. Shapiro J.D., Millward M.J., Rischin D. et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol. 63:1996;89-93.
97. Lund B., Hansen O.P., Theilade K. et al. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 86:1994;1530-1533.
98. Kunkel L.M., Evans S.S., Dottino P.R. et al. Cisplatin (CDDP) and gemcitabine (dFdC) in relapsed ovarian cancer. Proc Am Soc Clin Oncol. 17:1998;357. [abstract 1379].
99. Krakowski I., Petit T., Kayitalire L. et al. Gemcitabine in combination with cisplatin in advanced ovarian cancer: a phase II study. Proc Am Soc Clin Oncol. 17:1998;356. [abstract 1373].
100. Bauknecht T., Grieshaber C., Breitbach G.P. et al. Gemcitabine (GEM) in combination with cisplatin (CP) in previously untreated patients ≥60 years with FIGO stage IIIC or IV epithelial ovarian cancer: a phase II study: preliminary results. Proc Am Soc Clin Oncol. 17:1998;356. [abstract 1376].
101. Noguà M., Cirera L., Arcusa M. et al. Gemcitabine combined with cisplatin first line: a phase II study in patients with advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol. 17:1998;357. [abstract 1377].
102. Underhill C., Parnis F.X., Highley M. et al. A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer (EOC). Ann Oncol. 7(Suppl. 5):1996;69. [abstract 3240].
103. Rose P.G., Blessing J.A., Mayer A. et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 16:1998;405-410.
104. Sutton G.P., Blessing J.A., Homesley H.D. et al. Phase II trial of ifosfamide and mesna in advanced ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 7:1989;1672-1676.
105. Dimopolous M.A., Gennatas C., Papadimitriou C. et al. Ifosfamide and paclitaxel (IP) for previously treated advanced epithelial ovarian cancer (EOC). Ann Oncol. 7:1996;70.
106. Gordon A.N., Hainsworth J., Moore M. et al. Doxil (Doxorubicin HCl Liposome Injection) in the treatment of patients with refractory advanced ovarian carcinoma - results of an interim analysis. Proc Am Soc Clin Oncol. 17:1998;1345.
107. Kaye S.B., Piccart M., Aapro M. et al. Phase II trials of docetaxel (taxotere) in advanced ovarian cancer - an update overview. Eur J Cancer. 33:1997;2167-2170.
108. Stiff P.J., Bayer R., Kerger C. et al. High dose chemotherapy with autologous trasplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol. 15:1997;1309-1317.
109. Legros M., Dauplat J., Fleury J. et al. High dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long term results. J Clin Oncol. 15:1997;1302-1308.
110. Aghajanian C., Fennelly D., Shapiro F. et al. Phase II study of 'dose-dense' high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. J Clin Oncol. 16:1998;1852-1860.
111. Nemunaitis J., Poole C., Primrose J. et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res. 4:1998;1101-1109.